CLOSTRIDIUM DIFFICILE DIAGNOSTICS MARKET SIZE AND SHARE ANALYSIS - GROWTH TRENDS AND FORECASTS (2022 to 2030)

Clostridium difficile infection (CDI) is diagnosed with the help of conventional laboratory testing methods, however, rapid point-of-care diagnostic tests are also available, which can save time and costs significantly. Clostridium difficile is a disease caused by bacteria. The illness manifests as a variety of symptoms, such as diarrhea, nausea, and colon inflammation. Furthermore, since antibiotics kill healthy bacteria in the body and promote the growth of C. difficile bacteria, they are also responsible for clostridium difficile infection when taken frequently. Watery diarrhoea, dehydration, fever, nausea, loss of appetite, and weight loss are typical signs of clostridium difficile infection. Diagnostic assays used for detection of CDI include enzyme immunoassays (EIAs) for toxins A/B. However, these are no longer considered stand-alone primary tests due to poor sensitivity. Other tests include glutamate dehydrogenase enzyme immunoassay and molecular assay based on polymerase chain reaction. Isothermal amplification technology has also been approved by the U.S. Food & Drug Administration for diagnosis of CDI. Manufacturers such as Cepheid, BD Diagnostics, DiaSorin, Inc., Abbott Laboratories, Thermo Fisher Diagnostics, and Luminex Corporation offer advanced diagnostic tests for clostridium difficile infection. For instance, Cepheid GeneXpert test, Nanosphere Verigene SP by Luminex Corporation offer sensitivity and timely results for clostridium difficile infection.

Market Dynamics

Factors such as rising prevalence of clostridium difficile infection, availability of precise and advanced diagnostic techniques such as real time-polymerase chain reaction (RT-PCR), and presence of generic versions of standard antibiotics such as metronidazole is expected to boost growth of the clostridium difficile diagnostics and treatment market over the forecast period. Furthermore, various organizations and manufacturers are working towards increasing awareness about clostridium difficile infection and its severity. For instance, in March 2018, C Diff Foundation awarded its “Making a Difference” award to CutisPharma, Inc.—a pharmaceutical company, for contribution of the company towards increasing awareness and expanding treatment options.

Key features of the study:

• This report provides an in-depth analysis of the global clostridium difficile diagnostics market, and provides market size (US$ Million) and compound annual growth rate (CAGR%) for the forecast period (2022–2030), considering 2021 as the base year
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends,  regional outlook, and competitive strategies adopted by key players
• It profiles key players in the global  clostridium difficile diagnostics market  based on the following parameters – company highlights, products portfolio, key highlights, financial performance, and strategies
• Key companies covered as a part of this study include F. Hoffmann-La Roche Ltd, Thermo Fisher Scientific, Merck & Co., Inc., Pfizer, Inc., Actelion Pharmaceuticals, Inc., Abbott Laboratories, Trinity Biotech Plc., Summit Therapeutics, Sanofi S.A., Novartis AG, and AstraZeneca Plc
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
• The global  Clostridium Difficile Diagnostics market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts1
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global  Clostridium Difficile Diagnostics market

Detailed Segmentation:

• Global  Clostridium Difficile Diagnostics Market, By Diagnostic Test:
  • Enzyme Immunoassays
  • Real-Time Polymerase Chain Reaction (RT-PCR)
  • Nucleic Amplification Tests (NAAT)
  • Stool Test
    • GDH Antigen Test
    • Toxin A and B Test
  • Blood Test
  • Colonoscopy or Sigmoidoscopy
  • Others
• Global  Clostridium Difficile Diagnostics Market, By End User:
  • Hospitals
  • Diagnostic Centers
  • Specialty Clinics
  • Others
• Global  Clostridium Difficile Diagnostics Market, By Region:
  • North America
    • By Country
      • U.S.
      • Canada
  • Latin America
    • By Country
      • Brazil
      • Mexico
      • Argentina
      • Rest of Latin America
  • Europe
    • By Country
      • Germany
      • U.K.
      • France
      • Italy
      • Spain
      • Russia
      • Rest of Europe
  • Asia Pacific
    • By Country
      • China
      • India
      • Japan
      • Australia
      • South Korea
      • ASEAN
      • Rest of Asia Pacific
  • Middle East
    • By Country
      • GCC
      • Israel
      • Rest of Middle East
  • Africa
    • By Region/Country
      • South Africa
      • Central Africa
      • North Africa
• Company Profiles
  • F. Hoffmann-La Roche Ltd *
    • Company Highlights
    • Products Portfolio
    • Key Highlights
    • Financial Performance
    • Strategies
  • Thermo Fisher Scientific
  • Merck & Co., Inc.
  • Pfizer, Inc.
  • Actelion Pharmaceuticals, Inc.
  • Abbott Laboratories
  • Trinity Biotech
  • Summit Therapeutics
  • Sanofi S.A.
  • Novartis AG
  • AstraZeneca Plc

“*” marked represents similar segmentation in other categories in the respective section.